Proteomics in India: the clinical aspect by Somaditya Mukherjee & Arun Bandyopadhyay
Mukherjee and Bandyopadhyay  Clin Proteom  (2016) 13:21 
DOI 10.1186/s12014-016-9122-0
REVIEW
Proteomics in India: the clinical aspect
Somaditya Mukherjee and Arun Bandyopadhyay*
Abstract 
Proteomics has emerged as a highly promising bioanalytical technique in various aspects of applied biological 
research. In Indian academia, proteomics research has grown remarkably over the last decade. It is being extensively 
used for both basic as well as translation research in the areas of infectious and immune disorders, reproductive dis-
orders, cardiovascular diseases, diabetes, eye disorders, human cancers and hematological disorders. Recently, some 
seminal works on clinical proteomics have been reported from several laboratories across India. This review aims to 
shed light on the increasing use of proteomics in India in a variety of biological conditions. It also highlights that India 
has the expertise and infrastructure needed for pursuing proteomics research in the country and to participate in 
global initiatives. Research in clinical proteomics is gradually picking up pace in India and its future seems very bright.
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Background
The beginning of the twentyfirst century, saw the birth 
of a new technology called ‘proteomics’ that emerged 
as a highly promising bioanalytical technique in vari-
ous aspects of applied biological research. Though India 
could not play a role in human genome sequencing pro-
jects, the country has emerged as one of the frontrun-
ners in global proteomics research and has come a long 
way from where it was, probably a decade ago [1–3]. The 
importance of proteomics research was realized when 
many Indian researchers initiated identifying proteins 
critical to the pathophysiology of various diseases. How-
ever, the actual momentum gained subsequently when 
several laboratories were successful in arranging sophis-
ticated facilities for efficient proteome separation and 
detection using tissue as well as liquid samples. This was 
supported further with national efforts for network build-
ing and collaboration amongst various laboratories with 
a primary objective for early detection, diagnosis, and a 
way to therapeutics for common as well rare diseases.
Although the development of proteomics research in 
India was rather slow at the outset, the last decade or so 
has seen a dramatic expansion in the proteomics com-
munity [4]. Presently, there are over a hundred research 
laboratories in approximately 80 academic or research 
institutes across India involved in various proteome-level 
investigations. Thus it may safely be said that in the past 
few years, proteomics has emerged as a powerful tool 
for varied biological investigations in the country. Prot-
eomics is also becoming an attractive method of choice 
for the identification and development of new biomark-
ers and potential therapeutic targets. Increasing finan-
cial and infrastructure support from the government is 
likely to take proteomics research in the country to new 
heights.
Proteomics is a scientific approach that attempts to 
completely characterize the proteome (or subproteome) 
of a cell or tissue. Various technologies can be employed 
during the three major steps involved in proteomic anal-
ysis: sample preparation, separation of proteins or pep-
tides, identification and characterization of proteins, 
and the technologies can be mixed and matched to meet 
the needs to answer any particular biological or clinical 
question. The advancement of proteomic technologies 
now addresses the challenges associated with the patho-
physiology of various diseases. Proteins are most widely 
affected in disease, response and recovery. The most 
important application of proteomics is believed to be 
discovery of disease biomarkers and drug targets which 
can lead to designing of products aimed at diagnosis and 
treatment of diseases like cancer, cardiovascular diseases, 
obesity and type 2 diabetes. This application of proteomic 
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tools and knowhow to the field of medicine is called clini-
cal proteomics (Fig. 1). It encompasses the translation of 
proteomic detection technologies and strategies towards 
the production of diagnostics and therapeutics for the 
direct improvement of human health [5]. Therefore, 
clinical proteomics methods hold special promise for 
the identification of new biomarkers that might improve 
disease staging, risk stratification, and the prognosis and 
treatment of diseases. The following review intends to 
look into the current developments and shortcomings 
in India’s clinical proteomics scene and the problems 
faced by the Indian scientific community in translational 
research. The review also deals with next generation pro-
teomics methods and different proteomics databases 
developed in India.
Review
Proteomics in Indian academia and the emergence 
of Proteomics Society India
Proteomics is taking centre stage in biology and bio-
medical research in India. Several institutes are currently 
employing proteomics techniques in their research and 
at present, we have an enviable mass of proteomics sci-
entists in the country. To foster entrepreneurship and 
skill development in proteomics research, many bio-
tech parks have been established with public and pri-
vate support. In recent years, proteomics and related 
disciplines have also been incorporated into academic 
curricula across India due to their increasing impact on 
clinical research. For instance, The Clinical Proteomics 
Remote Triggering Virtual Laboratory (http://iitb.vlab.
co.in/?sub=41&brch=237) creates a virtual platform for 
beginners to acquire knowledge and a realistic experience 
of performing different techniques commonly applied 
in clinical proteomics research. These new e-learning 
resources in proteomics act as important global plat-
forms for students, e-learners and researchers. With 
expansion of research efforts and introduction of modern 
technologies, it is important to facilitate interactions 
among the proteomics fraternity and help them dissemi-
nate knowledge for the holistic development of this dis-
cipline. “Proteomics Society India”, is thus a step in that 
direction that provides a platform to pursue an agenda 
that will meet this objective. The Society which is deeply 
involved towards imparting education in proteomics 
research through organizing periodic conferences, work-
shops and meetings, is still in its infancy. However, a lot 
is being done to make students and teachers familiar with 
proteomics. Consequently, the 3rd Annual Meeting of 
PSI—International Proteomics Conference on ‘OMICS 
MEETS DISEASE’, was held at Kolkata in December 
2011. This was followed by a themed conference on 
‘Medical Proteomics’ in Bangalore in November,2013. 
Both the events were well attended by clinicians, eminent 
scientists and students. This highlights India’s emergence 
as a global player in cutting-edge clinical proteomics 
research.
Methods adopted for clinical proteomics research in India
In India, clinical proteomics efforts initially relied upon 
the traditional 2DE-MS approach and its advanced vari-
ation, 2D-DIGE. However, these gel-based protein sepa-
ration approaches offered limited proteome coverage. 
This resulted in a shift towards adopting alternative, high 
throughput shotgun approaches such as liquid chro-
matography–mass spectrometry (LC–MS or LC–MS/
MS). This approach, having greater quantitative ability, 
enabled deeper proteome analysis generating huge pro-
tein datasets. This gave way to semi quantitative labeling 
technologies such as isobaric tags for relative and abso-
lute quantitation (iTRAQ) and stable isotope labeling 
by amino acids in cell culture (SILAC). iTRAQ is a mass 
spectrometry based quantitative proteomics method that 
determines the amount of proteins from different sources 
in a single experiment using stable isotope labeled mol-
ecules that can be covalent bonded to the N-terminus 
and side chain amines of proteins [6–8]. Candidate tis-
sue, serum and drug resistance biomarkers have been 
discovered using this technique. SILAC is another mass 
spectrometry based quantitative proteomic technique 
that detects differences in protein abundance among 
samples using non-radioactive isotopic labeling [9–12]. 
It has emerged as a very powerful method to study cell 
signaling, post-translational modifications such as phos-
phorylation, protein–protein interaction and regulation 
of gene expression [13, 14]. SILAC has become particu-
larly important in the field of secretomics.
In general, mass spectrometry-a central tool used for 
monitoring, identifying and characterizing proteins has 
become an invaluable technique of choice for both pro-
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With an increasing ability to correctly characterize 
reduced quantities of samples and more complex mix-
tures of proteins and peptides, mass spectrometry is 
quickly becoming a key tool in the discovery of altera-
tions to the proteome thereby facilitating biomarker 
identification. Additionally, the possibility of using mass 
spectrometry directly in clinical assays is also becoming 
a reality because the technique has a low detection limit 
and can perform high throughput analyses. Though sci-
entists prefer the antibody based targeted approaches 
(ELISAs, TMAs) for confirmation and validation of 
markers, targeted quantitative approaches like MRM 
are becoming quite popular in the proteomics commu-
nity. MRM is highly reproducible and is able to replace 
expensive antibody-based quantification like Western 
blotting and ELISA. Many independent investigations 
have used this approach for targeted quantification. One 
such example is quantification of cancer related proteins 
in body fluids using targeted proteomics [15]. Multiple 
reaction monitoring (MRM) using mass spectrometry is 
a highly sensitive and selective method for the targeted 
quantitation of protein/peptide abundances in complex 
biological samples [16]. Parallel reaction monitoring 
(PRM) detects all product ions and identifies peptides 
with high  confidence. Thus, interference is reduced and 
specificity is increased in PRM. Qquantification in PRM 
is done by extracting one or more fragment ions that are 
selected post-acquisition. However, data visualization 
and analysis in PRM is similar to MRM [17]. Compared 
to MRM, PRM provides data with better mass accuracy 
and removes noise of interfering signals. In addition, 
PRM based targeted proteomics reduces assay develop-
ment time compared to MRM because in PRM, frag-
ment ions can be selected post-acquisition. The high 
scan speed facilitates development of sequential window 
acquisition of all theoretical mass spectra (SWATH). 
Peptides are quantitated by targeted extraction of 
SWATH-MS data. However, direct proteome profiling 
has remained a major technical challenge for body fluid 
proteomics particularly serum and plasma. Hence, it may 
be concluded that conventional tools for doing proteom-
ics research such as 2DE to separate a large number of 
proteins, spot picking, in-gel trypsin digestion of excised 
gel spots and MALDI–TOF–MS based identification are 
gradually giving way to more advanced proteomics tools.
Recent developments in next generation proteomics 
tools are yielding newer information in modern biology. 
MALDI imaging mass spectrometry (MALDI–IMS) is 
providing major contributions to the understanding of 
disease progression, improving diagnostics, and drug 
delivery. MALDI–IMS is a mass spectrometry based 
imaging technique which allows direct label free meas-
urement of biomolecules, metabolites and drugs at one 
time in tissue sections without destroying the sample [18, 
19]. Proteogenomics refers to use of proteomic informa-
tion, generated from mass spectrometry, to improve gene 
annotations [20–22]. Proteogenomic studies can also 
provide information about the presence of programmed 
frameshifts, N-terminal methionine excision, signal pep-
tides, proteolysis and other post-translational modifi-
cations [21]. Proteogenomics is becoming increasingly 
relevant in clinical research and biomarker discovery. 
Protein microarray is a sensitive and high throughput 
gel-free protein analysis method that is rapidly becom-
ing powerful for protein detection, protein expression 
profiling, diagnostics, biomarker discovery, protein–
protein interactions etc. These arrays are solid-phase 
ligand-binding assay systems using immobilized proteins 
of interest on surfaces which include membranes, glass, 
microtiter wells, mass spectrometer plates, beads etc. 
[23].
Studies in clinical proteomics carried out so far in India
As in other parts of the world, proteomics has been 
implemented by Indian researchers to elucidate bio-
logical mechanisms as well as to discover biomarkers 
for various diseases, enabled by advancements both in 
instrumentation and software. Considerable efforts have 
been made to explore the mechanism of disease patho-
genesis using animal models as well as cell biology and 
molecular biology techniques. The publications from 
these studies have emerged from major research insti-
tutes and University laboratories from across the country. 
Several research groups from India are actively pursuing 
cutting-edge research on proteomics of different infec-
tious and immune disorders, reproductive disorders, 
cardiovascular diseases, diabetes, eye disorders, human 
cancers and hematological disorders.
Infectious disease and immune disorders
Proteomics is employed as a study tool in tuberculosis 
which affects a large population in the country and is of 
major concern. Research institutes like National JALMA 
Institute for Leprosy & Other Mycobacterial Diseases, 
Agra and National Institute for Research in Tuberculosis, 
Chennai are the frontrunners in this area. The underly-
ing objective is to characterize the various strains, decod-
ing drug resistance and identifying biomarker candidates 
along with new therapeutic targets [24, 25]. Proteomics 
of clinical isolates of malarial parasites is undertaken by 
institutes such as IISc, Bangalore; ICGEB, New Delhi and 
IIT Powai, Mumbai. These efforts are providing insights 
into its physiology whereas proteomic analysis of serum 
from infected individuals gives preliminary information 
concerning potential biomarkers [26–29]. Several studies 
have also been conducted on clinical isolates of wild type 
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and drug resistant varieties of Leishmania across differ-
ent institutes of the country like NCCS, Pune; JNU, New 
Delhi; CDRI, Lucknow; IOB, Bangalore; AIIMS, New 
Delhi; NIPER, Mohali; BHU, Varanasi and IICB, Kolkata 
[30–44]. Interesting findings have also been reported on 
other infectious diseases like hepatitis, food poisoning, 
leprosy etc. [45–50]. Substantial research activities on 
some other immune disorders have also been carried out 
in centres like Bose Institute, Kolkata; PGIMER, Chandi-
garh; IOB, Bangalore; CDRI, Lucknow; IGIB, New Delhi 
and AIIMS, New Delhi using high throughput proteomic 
techniques [51–60].
Reproductive biology and respiratory disorder
Proteomic analysis of germ cells, seminal plasma and 
mammary epithelial cells is carried out at NDRI, Kar-
nal to know about fertility and lactation in dairy animals 
[61–63]. Proteomics studies on reproductive disorders 
such as endometriosis and polycystic ovarian syndrome 
have also been reported from institutes like IIT Kharag-
pur and NIRRH, Mumbai [64–66]. The effect of hypo-
baric hypoxia occurring at high altitude is also being 
analyzed by a research group at DIPAS, DRDO, New 
Delhi through proteomics methods [67].
Metabolic diseases
Proteomic technologies have also been used to under-
stand cardiovascular diseases like Cardiac Hypertro-
phy, CAD, MI, and RHD. Several renowned institutes 
like PGIMER, Chandigarh; IGIB, New Delhi; IICT, 
Hyderabad; Thrombosis Research Institute, Bangalore 
and IICB, Kolkata are involved in such initiatives [68–
75]. The difference between stenotic and non stenotic 
human plasma proteins has been investigated in the con-
text of rheumatic mitral valve disease which is prevalent 
in developing countries including India. Proteins, which 
manifest both inflammatory and thrombotic components 
have been identified in Rheumatic Mitral Stenosis at IICB, 
Kolkata using a label free proteomic approach, [75]. Very 
recently, iTRAQ based proteomic studies from IGIB, New 
Delhi have shown that downregulation of apolipoproteins 
and albumin might be responsible for impaired reverse 
cholesterol transport in stable CAD [76]. Interesting find-
ings in Type 2 diabetes have emerged from proteomic 
studies carried out at NCL, Pune in human plasma and 
drug induced animal models [77–85]. One of the novel 
initiatives undertaken by this group is to study advanced 
glycation end products (AGE) in a diabetic animal model 
using MALDI–TOF–MS based proteomics [82].
Eye disease
Proteomics research on various eye disorders like dia-
betic retinopathy, mycotic keratitis, dry eye syndrome 
and retinoblastoma tumors have been undertaken across 
institutes like SRM University, Kattankulathur; Aravind 
Medical Research Foundation, Aravind Eye Care System, 
Madurai and Sankara Nethralaya, Chennai [86–92].
Cancers and hematological disorders
The above studies help us to understand that proteom-
ics is now universally applied to study various types of 
circulating body fluids and other biological samples. For 
instance, proteome profiles of serum/plasma, other bio-
logical fluids and biopsy specimens from different types 
of cancers are currently being evaluated across centres 
like IISc, Bangalore; CCMB, Hyderabad; IOB, Banga-
lore; ACTREC, Mumbai and IIT Powai, Mumbai with 
necessary infrastructural support, scientific knowledge 
and technical expertise from the institutes as required 
[93–109]. Similar studies have been replicated for differ-
ent hematological disorders at SINP, Kolkata [110–113]. 
These examples give an idea of some of the areas where 
proteomic tools are being currently used.
Newer separation methods for pre-fractionation and 
histochemical quantification of stained tissue sections 
are gaining popularity by the day [114–123]. Exosomes, 
are also becoming an attractive starting material for the 
analysis of circulatory biomarkers. The impact of these 
studies on basic as well as biomedical research will only 
be felt in the years to come.
Different proteomics databases developed in India
With the expansion of protein sequence databases and 
search engines designed for direct input of mass spec-
trometry data, the high-resolution mass spectrometers 
with greater sensitivities can provide rapid and accu-
rate identification of proteins for any number of spe-
cies for which complete or partial genomes have been 
sequenced. This has lured scientists and data analysts to 
use proteomic methods in biomedical investigations and 
generate vast amounts of biological and molecular data 
that are invaluable to the global proteomics community. 
Such diverse datasets help to identify enzyme-substrate, 
signaling and coordination networks involved in vari-
ous biological processes, which in turn, can be helpful in 
molecular diagnostics and disease therapeutics. Progress 
in the field of proteomics will benefit substantially from 
the development of informatics programs which enable 
faster processing of complex datasets. Thus, bioinformat-
ics is one of the pillars of proteomics. Researchers at IOB 
(http://ibioinformatics.org), Bangalore have developed 
sophisticated bioinformatics tools like HPRD (www.hprd.
org), Human Proteinpedia (www.humanproteinpedia.
org/) and Human Proteome Map, a database on pancre-
atic cancers and several human signaling pathways [124–
126]. It is through creation of the ‘Human Proteome 
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Map’ that India received global attention recently. Using 
high-resolution mass spectrometry, independent drafts 
of the ‘Human Proteome Maps’ have been published by 
two investigator led groups which only highlights the 
biological significance of the data [126]. NetPath (http://
www.netpath.org)—the flagship database of IOB, con-
tains manually curated data for 36 human signaling path-
ways [127–134]. Signaling pathways such as Delta-Notch, 
EGFR1, Hedgehog, TNF-alpha have been curated at 
IOB, Bangalore. Particularly, the Wnt signaling pathway 
has been selected and organized for Cancer Cell Map 
(http://cancer.cellmap.org/cellmap/), which is a data-
base of pathways focusing on human cancer. NetSlim 
is a slimmer collective version of NetPath (http://www.
netpath.org/netslim/). It contains a graphical network of 
major signaling reactions [135]. Research teams at Lab 
SurgPath, Mumbai have contributed significantly to the 
Human Protein Atlas (http://www.proteinatlas.org/).
At the IMTECH, Chandigarh a curated database of 
proteins associated with cervix cancer—CCDB, a data-
base of anticancer peptides and proteins called Can-
cerPPD, and a database of hemolytic and non-hemolytic 
peptides—Hemolytik have been developed [136, 137]. 
NCBS has also come up with the DOQCS, which repre-
sents the collection of basic models of different signaling 
pathways [138–141]. Researchers at IISc, Bangalore have 
developed quite a few protein databases related to struc-
ture and function of protein kinases like ‘KinG’, NrichD, 
PALI, PRODOC and MulPSSM [142–144]. A number of 
protein databases such as PepBind, Immune Epitope Pre-
diction Database & Tools, SEDB, Clostridium-DT(DB), 
and VPDB have originated from the Center of Bioinfor-
matics in Pondicherry University [145–147]. Databases 
of protein features, resources for signaling and metabolic 
pathways intrinsic to specific biological processes, and 
repositories of disease-specific molecular level changes 
will help researchers use systems biology approaches to 
understand disease mechanisms in greater detail.
Conclusion
Clinical proteomics is yielding some fruitful results for 
Indian proteomics researchers utilizing state-of-the-art 
experimental and analytical methodologies. All these will 
benefit the proteomics community in the long run. How-
ever, these efforts are not enough for the benefit of the 
huge Indian patient population. Despite some success sto-
ries, India is still some distance away from successful trans-
lation of laboratory findings into clinical practice. India 
needs focused, sustained policies to promote translational 
research through specialized mega projects. Establishment 
of tissue repositories or registries is the need of the hour. 
The country’s overall healthcare infrastructure and medi-
cal informatics system also needs both public and private 
sector support on a long term basis so as to facilitate more 
effective translation studies. Tie-ups with commercial 
companies to facilitate technological developments will be 
necessary. At present, most of the proteomic investigations 
are arising from individual labs in research institutes of 
national repute. Almost all the studies are in the discovery 
phase. Collaboration between scientists and clinicians will 
facilitate the execution of well-designed multi-institutional 
and multi-centric studies aimed at addressing the relevant 
health problems unique to India, evaluating disease out-
comes and their validity.
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